The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1352-1354.e7 , December 2009

Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis

  • John W. Steinke, PhD

      Affiliations

    • Department of Medicine, University of Virginia Health Systems, Charlottesville
  • ,
  • Spencer C. Payne, MD

      Affiliations

    • Department of Otolaryngology—Head and Neck Surgery, University of Virginia Health Systems, Charlottesville
  • ,
  • M. Elizabeth Tessier, MD

      Affiliations

    • Department of Medicine, University of Virginia Health Systems, Charlottesville
  • ,
  • Lori O. Borish, RN

      Affiliations

    • Department of Medicine, University of Virginia Health Systems, Charlottesville
  • ,
  • Joseph K. Han, MD

      Affiliations

    • Department of Otolaryngology—Head and Neck Surgery, Eastern Virginia Medical School, Norfolk
  • ,
  • Larry C. Borish, MD

      Affiliations

    • Department of Medicine, University of Virginia Health Systems, Charlottesville

  • Image Result

    Change in CT score after budesonide nasal irrigation. Each dot represents an individual with a line connecting the prebudesonide and postbudesonide CT scores. The bold lines to the side of the data po

    Change in CT score after budesonide nasal irrigation. Each dot represents an individual with a line connecting the prebudesonide and postbudesonide CT scores. The bold lines to the side of the data points indicate the median, with the interquartile range and inner fence indicated with a box and whisker plot, respectively (P < .05 for prebudesonide compared with postbudesonide sinus score).

  • Image Result
    Self-assessed change in sinus symptom score after budesonide nasal irrigation. Each dot represents an individual, with a line connecting the prebudesonide and postbudesonide sinus scores. Lines to the

    Self-assessed change in sinus symptom score after budesonide nasal irrigation. Each dot represents an individual, with a line connecting the prebudesonide and postbudesonide sinus scores. Lines to the side of the data points indicate the mean ± SEM (P < .01 for prebudesonide compared with postbudesonide sinus score).

  • Image Result
    VAS for sinus symptoms. Each subject was asked to rate each of 16 symptoms. The range of symptoms was none to severe.

    VAS for sinus symptoms. Each subject was asked to rate each of 16 symptoms. The range of symptoms was none to severe.

  • Image Result
    Patient perception of sense of smell after budesonide nasal irrigation. Using a VAS, subjects were asked to assess their sense of smell before and after nasal irrigation. The VAS was converted to a di

    Patient perception of sense of smell after budesonide nasal irrigation. Using a VAS, subjects were asked to assess their sense of smell before and after nasal irrigation. The VAS was converted to a digital scale rated 0 (no smell) to 6 (no impairment in ability to smell). Each dot represents an individual with a line connecting the prebudesonide and postbudesonide scores, and the lines to the side of the data points indicate the means ± SEMs (P <.05 for prebudesonide compared with postbudesonide sense of smell).

  • Image Result
    Endoscopic scoring system. Modified from Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg 1997;117:S35-S40.E7

    Endoscopic scoring system. Modified from Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg 1997;117:S35-S40.E7

  • Image Result
    VAS for asthma symptoms. Each subject was asked to rate each of 6 symptoms.

    VAS for asthma symptoms. Each subject was asked to rate each of 6 symptoms.

 Supported by National Institutes of Health grant nos. RO1 AI01793 and PO1 AI50989. Disclosure of potential conflict of interest: J. W. Steinke has received research support from the National Institutes of Health. S. C. Payne has received honoraria from Acclarent, Inc, has received research support from the American Academy of Otolaryngologic Allergy, and has provided legal consultation or expert witness testimony on the topic of tonsillectomies. L. C. Borish is on the speakers' bureau for Merck, is on an advisory board for Genentech and Novartis, and has received research support from Genentech and Merck. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01406-7

doi: 10.1016/j.jaci.2009.09.018

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1352-1354.e7 , December 2009